11/4/2026

speaker
Conference Operator
Operator

Welcome to the MediCover Q32026 report presentation. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers. CEO John Stubbington and CFO Anand Patel. Please go ahead.

speaker
John Stubbington
CEO

Good morning, everybody. It's John speaking. Welcome to our Q3 results presentation. It's another consistent quarter where we've seen good growth, and it's our seventh quarter of year-on-year margin improvement, which is something that we're really proud of, particularly as it's another challenging sort of comparable quarter from the performance that we had a year ago. So that's pretty good. Let's just remind everybody that we made a decision to divest our business in India and that that was a transaction that was 1.2 billion euros. You can see that our shareholding of that is 66.1%. Thank you very much. You know, Medicover and local partners have sold 100%. So that's a complete exit for us. And that means that in this presentation that most of the figures unless stated are continuing operations. So it just tells you I don't think we should underestimate this That will help us reshape the business for some years to come. So it's exciting times for us. Let's focus back on the quarter. Organic growth of 8%. So it's a solid performance from us. You know, 2% negative FX impact. You can see EBIT is up 22%. So that's really good movement for us. A continuing trend that we've established, which of course we It also comes at a time where we're actually repurposing a lot of our facilities. And if you look back over the course of the last 12 months, the 118 units we've actually closed. So we've been opening units at the same time, but closing a lot of units at the same time. And of course, As you close units, revenue goes immediately. As you open units, it takes a bit of time for that revenue to build. So that's in our mix and will continue to be in our mix for a while. Healthcare services revenue was solid and sports and wellness business has a consistent trend, which Thank you very much. And you can see that leverage decreased over the quarter, which is really good for us. So good revenue, good growth, a very positive movement on our adjusted EBITDA, as you can see, plus 7.1%. And our margin has a pleasing trend, taking us from 17.6 to 17.8. Healthy cash flow and, as I say, leverage down. If we look at the revenues across the group, if you look at this graph, it's slightly different than normal. On the left-hand side in the light blue, I think, is the whole business. And as we go to the dark blue, we start to look at the continuing business. the difference. We move well in terms of revenue, plus 6%. So still healthy growth for us. And as you look at it by country, healthy growth by Poland. We've got a bit of work to do when it comes to Germany and Romania. But we're well aware of that and got plans in place. And revenue by payer, you can see we strengthened again in the fee-for-service payer, which is very positive for us for the reasons that I explained before. It's also our major payer, which means that people have got a choice of who they use and who they decide to use. So if they're choosing goods, that's always a good sign. you can see the governmental income is flat due to all the micro changes that we've talked about before which we're managing and it's nice to see if you look at the funded revenue that there's a plus five percent there and we're doing a lot of work in that particular sector that is looking quite positive for us if we look at healthcare services organic growth of eight percent With margin expansion, so very good indeed. You see the revenue up is 6%. Price is approximately 6.3. FX is 1.9. FIFA service and other services perform well, which is good. And sports and wellness, we talked about before, has been strong and we continue to open facilities. And I think we'll be accelerating that not only in Q4, but beyond. Members, Poland grew. So Poland had an increase in members. Romania, we talked about last quarter in terms of some of our account management. So we're seeing the adjustments that occur there. And then our ongoing relationships with customers that are either paying us regularly or they're part of our loyalty schemes, etc. We're building that consistently. You can see that's 4.1 million people now from 3.6 million. Revenue, we've kind of talked about revenue by country, Poland healthy. You can see in the other country, that's mainly due to the repurposing in terms of the property and Romania relates to the membership. A big margin is very good. You can see 19.1 to 19.8. So very pleased about that and happy for the team. Got a really strong membership base at 1.5 million. And revenue by payer, you can see each one of them is up. So that's really, really good. Diagnostic services, really solid results. fee-for-service growth. So we explained the importance of that earlier in my conversation. Revenue is pleasing and consistent. You can see quite a bit of that is coming from price, and that shows the strength of our fee-for-service. Very consistent in terms of building the for service revenues in this area. Germany, a little bit softer this quarter. We believe that's a temporary position due to some of the vacation patterns that occurred and some lower activity that should come back. We continue to increase our BDPs, particularly in Poland. We want to strengthen our position here. Lab tests are up, so it's very solid, very consistent. You can see the revenue up 6.3%, very steady margin, slight change there in terms of the margin. But again, we think we can manage that over time. Test increase is pretty good. Revenue by country, it's all up. And if you look at the payer mix, it's a much stronger mix. And that's a trend that's been happening for quite a period of time. So all credit to the team. That should strengthen our position. We've added one extra slide for you related to some exciting developments that we have with our genetics team. We want to give you more detail on our MRD product launch. It's exciting times for them. Basically, we've got a simple blood test that detects early signs of lung cancer returning. So when a patient has their treatment, the traditional method for people to be able to see if anything has happened and they've got the clear, of course, is scans and testing. But with this, the blood test can be done a lot earlier and a lot simpler because it doesn't rely on there being tumor tissue for them to be able to so it's blood-based which means that we can do monitoring earlier maybe and actually do it more frequently and the indications are that that picks up if there is an issue 7.4 months earlier and of course this is all evidence-based it's the methodology we think can transfer to other things so we can expand it and we've actually launched this product now so We wanted to signpost this literally to really get the word out that we've made this development. We've worked on it for a long period of time. We've mentioned it before, but we really wanted to get it out there. So I'll now hand over to Anand, who will talk through some of the financials in a bit more detail. Anand, over to you.

speaker
Anand Patel
CFO

Thank you, John, and good morning, everyone. So in summary, I'd say another solid quarter from us with good organic growth and margin accretion year on year. John's mentioned that our total revenues were up 6% with organic revenues of 8%. Bear in mind, that's on a continuing basis. And John said, you know, most of the numbers in this slide are based on a continuing basis. If you look on a total basis for a comparator to Q2, our total revenues would be up 8% and our organic revenues will be double digit. In terms of good, from a profitability perspective, there were good flow through from the revenue numbers into our profits. So EBIT in particular, you can see at 49.3 million. That's for margin rate improvement, 110 basis points year on year, which is very good. And EBITDAO, which is our cash profit, which we focus on very strongly. You can see there's good growth in terms of year on year growth to 70.9 million with rate of 70 basis points year on year. That all naturally flows into a stronger EPS of just over 16 euro cents per share. In terms of in healthcare, strong organic revenue growth of 8%, with price driving 6%. Good margin growth across all measures, I'd say. So EBITDA is up 70 basis points year on year, and EBITDA is up 90 basis points year on year. From medical cost ratio perspective, it is better in the quarter. That's kind of masked by a kind of a mix into scaling in our sports businesses, but still the underlying medical cost ratios are strong. And in terms of the business unit performances, John's mentioned it, we were strong in sports and ambulatory in Poland, slightly offset by hospitals in Poland and Romania. In terms of diagnostics, So good organic growth again of 8.5%, split roughly 50-50 between price and volume. From an EBITDAO perspective, margins were flat year-on-year at 14.3%. And from an EBITDAO perspective, margins were marginally down 20 basis points. That's largely due to softness in Germany and genetics being offset by stronger performances in Poland, Romania, and the SSE. What we are doing, given the ongoing changes to reform in Q4, is taking action. So we took some action in Q3 and we'll take further actions in Q4 to make sure we're in good shape for the changes in 2027. In terms of other financial metrics, as our EBIT grows and our balance sheet remains broadly stable, our leverage comes down, which is good, so down to 2.7. Our ROIC is up from the start of the year to 14% from 13%. Effective tax rate of 28% for the quarter. I've mentioned previously we will be between 26% to 30% for the year. That remains the case. From a cash flow perspective, a bit of a timing issue. So still strong cash generation, let's be honest. There's strong profits flowing into the business. But there's a bit of timing in Q3 from a cash flow perspective. Some of it is in the base from last year and some of it will kind of revert into Q4. So overall, I think, you know, pretty strong, pretty solid in terms of other metrics. In terms of the usual capex slide, you can see to the left that actually there's still ample headroom between our free cash flow and our investment capex, which is good. On the right, you can see in terms of the percentage spend of revenue, so we spent 5.1% of revenues in Q3, largely 50-50 between maintenance and growth, and two-thirds of it as normal on healthcare services, and the third on diagnostics. In terms of capex for the full year, it will still be between 6% to 6.5%, as previously mentioned. in terms of medical space broadly unchanged quarter on quarter at just over a million square meters. And finally, from a targets perspective, we stand by the targets that we've set before for now. So we've had a strong seven quarters, as John says. And until there is a call on the closure of the Indian operation, we'll be sticking with these targets. With that, I'll hand you back to John.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation